GC Aesthetics (“GCA”), a medical technology company providing aesthetic solutions for global healthcare markets, announced today that the company has raised $97 million of new capital. The financing comprises a combination of debt, provided by Hayfin Capital Management (“Hayfin”), and an equity investment from GCA’s existing investors, including Montreux Equity Partners, Barry’s Tea and Oyster Capital Partners.
Proceeds from the financing will be used to refinance GCA’s outstanding debt, to fund advancement of an IDE study to support FDA approval of the Company’s breast implant products in the United States, and to fund additional product innovation and growth initiatives at GCA.
“We are very pleased with the strong support from our existing investors and are delighted to have Hayfin, who is a preeminent lender in the healthcare space, as our new lending partner,” commented Carlos Reis Pinto, Chief Executive Officer of GCA. “This financing, along with our continued solid financial performance, validates the strength and potential of our global, vertically-integrated healthcare aesthetics implant business. Additionally, the refinancing of our existing debt provides GCA with financial flexibility to pursue strategic growth initiatives, including the possibility of entering the U.S. market with our competitively differentiated products.”
Howard Rowe, Managing Director and Head of Healthcare at Hayfin, stated, “Hayfin looks to back innovative, high-growth healthcare businesses and our investment in GCA, with its leadership position in its key markets and global expansion plans, is consistent with this strategy. We look forward to partnering with GCA’s management team to help achieve the Company’s strategic growth objectives and capitalize on the opportunities for GCA to expand its position in the global aesthetics industry.”
About GC Aesthetics
GC Aesthetics (“GCA”) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel safe and confident on their personal journey. Through 30 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 2.5 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically-integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.
About Hayfin Capital Management
Hayfin Capital Management is a leading European-headquartered credit platform that provides lending solutions to corporates and asset management services to institutional clients. Since it was founded in 2009, Hayfin has extended more than €14bn in loans to over 285 companies. The firm’s total assets under management are valued at c.€10 billion. Hayfin makes public and private investments across the liquidity spectrum through five strategies: direct lending, special opportunities, high-yield credit & syndicated loans, securitized credit, and private equity funds. Hayfin has a diverse international team of over 90 experienced industry professionals. The firm is headquartered in London and has offices in Frankfurt, Madrid, Paris, Luxembourg, New York, and Tel Aviv. Hayfin is authorized and regulated by the Financial Conduct Authority. Further information can be found at hayfin.com.
Contacts GC Aesthetics info@gcaesthetics.com